Long-Term Effects of Neonatal Exposure to Hydroxylated Polychlorinated Biphenyls in the BALB/cCrgl Mouse by Martinez, Jeanelle M. et al.
1022 VOLUME 113 | NUMBER 8 | August 2005 • Environmental Health Perspectives
Research
Evidence that estrogen acts as a gynecologic
carcinogen comes from cases of adenocarci-
noma and nonneoplastic abnormalities of the
genital tract in females who had been exposed
to diethylstilbestrol (DES) in utero (Herbst
et al. 1971; Robboy et al. 1977). The subse-
quent cases of cancer and other gynecologic
abnormalities in females exposed to DES
in utero helped to establish the paradigm that a
developing fetus is sensitive to compounds tol-
erated by adults. This paradigm led researchers
to reexamine the potential effects of endocrine-
disrupting chemicals in human and wildlife
species (Gray 1998; Santodonato 1997;
Semenza et al. 1997; Zou and Fingerman
1997).
In mice, neonatal exposure to potent natu-
ral and synthetic estrogens results in the devel-
opment of cervicovaginal (CV) tumors, some
of which resemble tumors in human females
exposed to DES in utero (Bern et al. 1975;
Bern and Talamantes 1981). Most signifi-
cantly, these tumors in the mouse model, like
those in women transplacentally exposed to
DES, are dependent on the dose and time of
exposure to the estrogen. Correlation of estro-
genicity of DES with carcinogenicity has been
demonstrated in the mouse uterus but requires
an endogenous source of estrogen for both
tumor initiation and progression (Newbold
et al. 1990). 17α-Estradiol is a natural estrogen
that binds weakly to the estrogen receptor
(ER). In mice, exposure to 17α-estradiol dur-
ing a critical period of reproductive tract
development leads to subsequent gynecologic
malignancies (Hajek et al. 1997). These studies
exemplify that various abnormalities in long-
term studies are dependent on when mammals
are exposed to a natural or synthetic estrogen.
Although there are many known estrogenic
chemicals, we were interested specifically in
estrogenic hydroxylated polychlorinated
biphenyls (OH-PCBs) because the role they
play in breast cancer is controversial and
uncertain (Adami et al. 1995; Aschengrau
et al. 1998; Krieger et al. 1994). PCBs belong
to a class of organochlorine synthetic chemicals
that have up to 209 congeners or configura-
tions possible, depending on the number and
location of chlorines on the molecule. These
PCBs vary in the number of chlorine atoms
present, which ranges from 1 to 10, as well as
their position on the two benzene rings. The
relative toxicity of PCBs depends upon chemi-
cal characteristics such as chlorination,
hydrophobicity, and planarity (Brouwer et al.
1999). The biologic activity of PCBs is gener-
ally classiﬁed as dioxin-like or nondioxin-like
depending on their mechanism of action.
Dioxin-like compounds assume a coplanar
conﬁguration with chlorine atoms on the meta
or para benzene position and have a high bind-
ing afﬁnity to the aryl hydrocarbon receptor
(AhR). Through activation of the AhR, they
elicit dioxin-like biochemical and toxic
responses. Nondioxin-like chemicals assume a
noncoplanar configuration with chlorine
atoms on the ortho benzene position and bind
with variable affinities to steroid hormone
receptors. Certain PCBs found in the environ-
ment have been shown to be are estrogenic; for
example, Hansen et al. (1995) demonstrated
that landfill-associated extracts containing
PCBs are uterotropic in prepubertal rats. PCB
congeners that are capable of binding to the
ER can induce the following estrogen-related
effects in rodents: increased uterine wet
weight, increased glycogen content, prolonged
estrous cycle, and proto-oncogene expression
(Ecobichion and MacKenzie 1974; Gellert
1978; Korach et al. 1988). 4-OH-PCBs are
the major metabolites of PCBs. They are
found in human and wildlife blood and
appear to persist and bioaccumulate (Bergman
et al. 1994; Hovander et al. 2002; Li et al.
2003). 4-OH-PCBs are formed by an arene
oxide intermediate catalyzed by phase I
cytochrome P450 enzymes. However, the
toxicologic impact of the OH-PCBs and their
adverse effect in humans are not well charac-
terized. The placental transfer of OH-PCBs
has been recently established (Soechitram et al.
2004), suggesting that these PCB metabolites
could have adverse effects during develop-
mental exposure. OH-PCBs have been shown
to be antiestrogenic and estrogenic and to
bind to the ER and to the thyroid hormone
receptor, and they are, in general, endocrine-
disrupting chemicals (Arulmozhiraja et al.
2005; Connor et al. 1997; Kitamura et al.
2005; Korach et al. 1988).
The goal of this study was to determine if
neonatal exposure to the estrogenic chemicals
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The neonatal mouse model has been a valuable tool in determining the long-term effects of early
exposure to estrogenic agents in mammals. Using this model, we compared the effects of 2´,4´,6´-
trichloro-4-biphenylol (OH-PCB-30) and 2´,3´,4´,5´-tetrachloro-4-biphenylol (OH-PCB-61) as
prototype estrogenic hydroxylated PCBs (OH-PCBs) because they are reported to exhibit relatively
high estrogenic activity both in vivo and in vitro. The purpose of this study was to examine the
relationship between estrogenicity and carcinogenicity of OH-PCB congeners. The OH-PCBs were
tested individually and in combination to determine whether effects of combined OH-PCBs dif-
fered from those of these OH-PCBs alone. We evaluated the long-term effects of neonatal exposure
to OH-PCBs with treatment doses that were based on the reported binding affinity of specific
OH-PCB congeners to estrogen receptor α. BALB/cCrgl female mice were treated within 16 hr
after birth by subcutaneous injections every 24 hr, for 5 days. The mice treated with OH-PCB-30
(200 µg/day) or 17β-estradiol (5 µg/day) showed similar increased incidences of cervicovaginal
(CV) tract carcinomas (43% and 47%, respectively). In addition, when mice were treated with
OH-PCBs as a mixture, a change in the type of CV tract tumor was observed, shifting from pre-
dominantly squamous cell carcinomas to adenosquamous cell carcinoma. From our results, we con-
clude that the individual OH-PCBs tested were estrogenic and tumorigenic in mice when exposed
during development of the reproductive tract. These data support the hypothesis that mixtures may
act differently and unexpectedly than do individual compounds. Key words: BALB/cCrgl mouse,
estrogenicity, female reproduction, hydroxylated polychlorinated biphenyls, OH-PCBs, tumori-
genicity. Environ Health Perspect 113:1022–1026 (2005). doi:10.1289/ehp.7735 available via
http://dx.doi.org/ [Online 20 April 2005]2´,4´,6´-trichloro-4-biphenylol (OH-PCB-30)
and 2´,3´,4´,5´-tetrachloro-4-biphenylol
(OH-PCB-61) results in carcinogenicity. The
positions of the chlorines for these two PCBs
are indicated in Figure 1. The OH-PCBs are
the 4-hydroxylated metabolites of parent
PCB-30 and PCB-61. We chose these PCB
congeners because they have known estro-
genic activity and their binding afﬁnity to the
ER is reported in the literature (Table 1).
Investigations of early-life-stage exposure to
polychlorinated biphenyls (PCBs) are war-
ranted because these organochlorine chemicals
and their metabolites readily cross the placenta
to the fetus in both humans and rodents and
are transferred through breast milk to the new-
born (Ando 1978; Ando et al. 1985, 1986).
There is a growing database on developmental
effects for endocrine-disrupting chemicals with
multiple end points, including cancer. In this
study, we examined the neonatal effects of
OH-PCBs. Although the specific OH-PCBs
investigated in this study may not occur in the
environment, they are sound prototypes for
estrogenic OH-PCBs that bind to ER-α and
elicit estrogen-mediated responses.
Materials and Methods
Chemicals. All chemicals were of the highest
grade available. 17β-Estradiol (E2) was pur-
chased from Sigma Chemical Co. (St. Louis,
MO). Both OH-PCB-30 and OH-PCB-61
were generously provided by S. Safe (Texas
A&M University, College Station, TX).
These OH-PCBs were synthesized and purity
conﬁrmed as described previously (Safe et al.
1995). For this study, E2 and the OH-PCBs
were dissolved in 1 mL 100% ethanol and
warmed to dissolve the chemical. Sesame oil
was added to obtain the desired concentra-
tions for 20-µL subcutaneous injections.
Ethanol was then evaporated using nitrogen
gas while keeping the solution warm to pre-
vent recrystallization. OH-PCB doses used in
this study are based on their reported respec-
tive binding affinity to ER-α. E2 (5 µg/day)
was used as a predictive dose because the fre-
quency of CV tumors in BALB/cCrgl mice
neonatally exposed to E2 is approximately
50% (Jones and Bern 1979). To test for inter-
active effects, doses were selected using the
high dose of OH-PCB-30 as a basis of com-
parison because it has a higher binding afﬁnity
to ER-α.
Animals. Mice were handled according to
the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal
Resources 1985), and the Institutional
Animal Care and Use Committee approved
all procedures performed on animals. Adult
mice were fed Purina Rodent Chow 5001
(Alies Seed, Houston, TX). Pregnant female
BALB/cCrgl mice were purchased from
Harlan Sprague Dawley (Indianapolis, IN).
The inbred BALB/cCrgl strain was used
because it has a low mammary tumor inci-
dence and its response to E2 treatment during
neonatal development is well documented.
Beginning within 16 hr after birth, female
pups were pooled from several litters and
distributed four or ﬁve pups per mother per
cage. Each cage was then given five daily
subcutaneous injections with 20 µL sesame
oil alone, 5 µg E2, 2.5 µg E2 plus 100 µg
OH-PCB-30, 20 µg OH-PCB-30, 200 µg
OH-PCB-30, 40 µg OH-PCB-61, 400 µg
OH-PCB-61, 10 µg OH-PCB-30 plus 10 µg
OH-PCB-61, or 100 µg OH-PCB-30 plus
100 µg OH-PCB-61 (Table 2). Animals were
weaned 21 days of age. Mice were examined
daily for premature vaginal opening for the
ﬁrst 35 days of life and checked monthly with
blunt forceps to detect concretions (calcium
carbonate deposits in the vagina that are a
result of malformation of the urogenital tract
in developmentally estrogenized animals).
When concretions were found, they were
removed. All mice that survived to 20 months
of age were sacrificed by CO2 fixation.
Tissues were dissected and fixed in 10%
buffered formalin for at least 24 hr before
being embedded in parafﬁn. Parafﬁn-embed-
ded blocks were serially sectioned and stained
with hematoxylin and eosin (H&E).
Statistical analyses. We used one-way
analysis of variance to assess differences in
body weight, uterine weight, and vaginal
opening. Pairwise comparisons of each experi-
mental group versus sesame oil control were
made by Tukey-HSD (honest signiﬁcant dif-
ference) tests. Survival comparisons were
made by Wilcoxon rank sum tests. The pro-
portions of animals with malignant tumors
were compared by Fisher exact tests. Animals
that died before the appearance of the first
tumor were excluded from the analysis.
Results
Gross observations. A biologic index of sexual
maturity can be visually assessed by day of vagi-
nal opening (DVO). The DVO was signifi-
cantly shorter in mice given E2 alone, E2 plus
OH-PCB-30 (200 µg), OH-PCB-61 (40 and
400 µg), and the mixture OH-PCB-30/61
(100/100 µg; Table 2). There was a dose-
dependent effect with the higher dose yielding
the shortest DVO. The lower doses of
OH-PCBs had a DVO similar to that in con-
trol mice. Body weight was significantly
decreased in mice given 5 µg E2. Mortality was
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Table 1. Chemical nomenclature, abbreviations, and ER-α binding.
Chemical name Abbreviation C50
a Observed log IC50
b
17β-Estradiol E2 1 0.837
2´,4´,6´-Trichlorobiphenyl PCB-30 — 6.77
2´,4´,6´-Trichloro-4-biphenylol OH-PCB-30 42 2.84
2´,3´,4´,5´-Tetrachlorobiphenyl PCB-61 — NDc
2´,3´,4´,5´-Tetrachloro-4-biphenylol OH-PCB-61 95 2.15
aThe molar equivalent required to occupy 50% of the mouse uterine ER-α binding site (Korach et al. 1988). bThe concen-
tration of competitor predicted to cause a 50% reduction in speciﬁc binding of radiolabeled 17β-estradiol to calf uterine
ER. cNot detected (ND) at doses tested (Kramer and Giesy 1999).
Figure 1. Chemical structures for OH-PCB-30 (A)
and OH-PCB-61 (B).
OH
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Table 2. Gross observations from neonatally treated BALB/c mice at 20 months of age.
Neonatal treatment DVO Body weight Mortalitya
(µg/pup/day) (mean ± SE) (g; mean ± SE) (%) No.b
Oil 23.8 ± 0.6 25.0 ± 0.37 9 35
E2 (5) 10.5 ± 0.4* 23.0 ± 0.43* 16 43
E2 (2.5) plus OH-PCB-30 (100) 10.9 ± 0.4* 24.8 ± 0.50 21 24
OH-PCB-30 (200) 11.1 ± 0.2* 24.6 ± 0.40 31** 32
OH-PCB-30 (20) 24.8 ± 0.4 24.8 ± 0.51 21 39
OH-PCB-61 (400) 12.4 ± 0.4* 24.7 ± 0.40 33** 33
OH-PCB-61 (40) 17.7 ± 0.8* 25.0 ± 0.44 19 31
OH-PCB-30/61 (100 + 100)c 12.1 ± 0.4* 25.7 ± 0.62 30** 27
OH-PCB-30/61 (10 + 10)c 22.4 ± 0.6 25.3 ± 0.33 18 40
DVO, day of vaginal opening. Pups were treated as described in “Materials and Methods.” 
aPercentage of animals that died before the end of the study. bNumber of animals used for study. cEqual concentrations
of OH-PCB-30 and OH-PCB-61 were used as a mixture. *p < 0.05 versus sesame oil control (Tukey-HSD test). **p < 0.05
versus sesame oil control (Wilcoxon rank sum test).increased in mice given OH-PCB at high doses
(p < 0.05; Table 2).
Tumor incidence. Tumor incidences are
summarized in Table 3. The only tumor seen
in control mice was one malignant lym-
phoma. The incidence of malignant tumors
was signiﬁcantly greater in all groups exposed
to E2 and/or PCB than in controls. Among
mice given E2 alone, incidence of CV tract car-
cinomas was 43% (16 of 37), and for any
tumor, 49% (18 of 37; some mice had more
than one type of tumor detected). We detected
other tumors that are commonly observed in
mice neonatally treated with E2, including
cholangiocarcinoma of the gallbladder and
granulosa cell tumor. The E2-treated mice
also had one incidence of bronchoalveolar
adenoma of the lung. Among mice given E2
plus OH-PCB-30, incidences of CV tract car-
cinomas (47%; 9 of 19) and granulosa cell
tumors (15%; 3 of 19) were significantly
increased. In addition, there was one reticu-
lum cell sarcoma detected in mice treated
with E2 plus OH-PCB-30.
In mice given the high dose of OH-PCB-30
(200 µg/pup/day), the incidences of CV tract
carcinomas and granulosa cell tumors were
45% (10 of 22) and 14% (3 of 22), respec-
tively; one mouse was found with cholangio-
carcinoma. Incidences of tumors in the
low-dose OH-PCB-30 mice (20 µg/pup/day)
were as follows: CV tract carcinomas, 6% (2
of 33); mammary gland adenocarcinoma,
15% (5 of 33); and bronchoalveolar adenoma/
carcinoma, 9% (3 of 33).
In mice neonatally treated with 400 µg
OH-PCB-61, we found a 20% incidence of
CV tract carcinomas (5 of 24), 4% incidence
of mammary gland adenocarcinoma (1 of
24); and an 8% incidence of hemangio-
sarcoma (2 of 24). From all of the treatment
groups, we observed one animal with hepato-
cellular carcinoma—a mouse treated with
400 µg OH-PCB-61. In mice treated with
the low dose of OH-PCB-61 (40 µg), tumor
incidences were as follows: CV tract carcino-
mas, 13% (4 of 30); granulosa cell tumor,
10% (3 of 30); mammary gland tumors, 13%
(4 of 30); and hemangiosarcomas, 7% (1 of
30). In mice given 200 µg of the mixture
(OH-PCB-30/61), the incidences of neo-
plasms detected were as follows: CV tract car-
cinomas, 38% (8 of 21); granulosa cell tumor,
10% (2 of 21); malignant lymphomas, 10%
(2 of 21); and bronchoalveolar carcinoma,
5% (1 of 21). Incidence rates for mice treated
with 20 µg OH-PCB-30/61 were 8% (3 of
36) for CV tract carcinomas, 3% (1 of 36) for
granulosa cell tumor, and 8% (3 of 36) for
mammary gland carcinomas.
Interactive effects of chemical mixtures.
The two types of tumors detected in groups
administered estrogenic compounds alone and
in combination were compared by Fisher exact
tests (Table 4). We observed no detectable dif-
ferences in the overall incidence of CV tract
tumors. However, there was a difference in the
relative distributions of tumor types. In 8% (3
of 37) of animals treated with E2 and in 14%
(3 of 22) of animals treated with 200 µg
OH-PCB-30, we observed a signiﬁcant differ-
ence between the combined incidences of CV
tract adenosquamous cell carcinoma compared
with that of animals treated with E2/OH-
PCB-30 (32%; 6 of 19), as determined using
Fisher exact tests. Although it was not statisti-
cally signiﬁcant, there appeared to be a trend
for an increased incidence of CV tract develop-
ment of adenosquamous cell carcinoma versus
squamous cell carcinoma when comparing the
combined incidence of OH-PCB-30 (14%; 3
of 22) and OH-PCB-61 (8%; 2 of 20) to that
of OH-PCB-30/61 (24%; 5 of 21).
Discussion
In this study, we used the DES neonatal
mouse model to evaluate the tumorigenic
effects of estrogenic OH-PCBs. The results
show that the production of CV tract tumors
occurred to a similar degree between 5 µg E2
(43%; 16 of 37) and 200 µg OH-PCB-30
(47%; 9 of 19). A rather large number of dif-
ferent tumors were detected in this study, but
the tumors with the highest frequency were
the CV tract tumors (Table 3). These CV
tract tumors were induced by neonatal
OH-PCB treatment. A limitation of this
study was the number of doses used, but there
appeared to be a pattern of increased CV-tract
tumors with the higher doses. These data
strongly support the theory that relatively
weak estrogens can induce tumors in mice
when exposure occurs during a critical period
of development (Hajek et al. 1997).
The neonatal mouse model has been exten-
sively studied for more than four decades and
has proven extremely valuable in assessing
human in utero exposure to DES. The deﬁned
period for causation of genital tract tumors by
natural (17α-estradiol and E2) and synthetic
(e.g., DES) estrogens occurs during the
development of the reproductive tract in both
humans and rodents (Hajek et al. 1997). The
use of the neonatal mouse model was necessary
because, unlike findings in adult-treated
rodents (Liehr et al. 1986), an apparent correla-
tion between estrogenicity and carcinogenicity
exists in neonatally treated rodents (Newbold
et al. 1990, 1997). In addition, species-speciﬁc
E2-mediated tumor induction occurs in differ-
ent strains of mice. For example, outbred
female CD-1 mice are susceptible to uterine
tumors, and inbred BALB/cCrgl mice are hor-
monally susceptible to CV tract tumors (Jones
and Bern 1977). E2-mediated tumor induction
is also age dependent and dose related and,
most important, occurs in a tissue-dependent
manner (Newbold et al. 1990).
Martinez et al.
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Table 3. Summary of specific tumor incidence in BALB/c mice treated neonatally and sacrificed at
20 months of age.
Neonatal treatment Incidence of tumor type
(µg/pup/day) ML H BA C CV OG MG Ota TNTb No.c
Oil 1 0 0 0 0 0 0 0 1 33
E2 (5) 0 0 1 2 16** 1 1 0 18** 37
E2 (2.5)/OH-PCB-30 (100) 0 0 0 0 9** 3* 0 1 11* 19
OH-PCB-30 (200) 0 0 0 1 10** 3 0 0 12* 22
OH-PCB-30 (20) 0 0 3 0 2 0 5 0 9* 33
OH-PCB-61 (400) 0 2 0 0 5* 0 1 2 11* 24
OH-PCB-61 (40) 2 1 0 0 4* 3 4* 2 15* 30
OH-PCB-30/61 (100 + 100)d 2 0 1 0 8* 2 0 2 13* 21
OH-PCB-30/61 (10 + 10)d 0 0 0 0 3 1 3 1 8* 36
Abbreviations: BA, bronchoalveolar; C, cholangiocarcinoma of the gallbladder; CV, cervicovaginal tract carcinoma; H,
hemangiosarcoma; OG, ovarian granulosa cell tumor; MG, mammary gland carcinoma; ML, malignant lymphoma; OG,
ovarian granulosa cell tumor; Ot, other types of tumors not listed; TNT, total number of tumors found in that treatment
group. Pups were treated as described in “Materials and Methods.” 
aTumor type occurred in no more than one animal per group. bSome mice had more than one type of tumor. cNumber of
mice diagnosed by H&E staining. dEqual concentrations of OH-PCB-30 and OH-PCB-61 were used as a mixture. *p < 0.05
versus sesame oil control (Fisher exact test). **p < 0.01 versus sesame oil control (Fisher exact test).
Table 4. Interactive effects on frequency of carcinoma types in the CV tract.
Neonatal treatment Percent frequency
(µg/pup/day) Total incidencea Squamous Adenosquamous
E2 (5) 16/37b 41 (15/37) 8 (3/37)
OH-PCB-30 (200) 10/22b 36 (8/22) 14 (3/22)
OH-PCB-61 (400) 5/24 13 (3/24) 8 (2/24)
E2 (2.5)/OH-PCB-30 (100) 9/19 16 (3/19) 32 (6/19)*
OH-PCB-30/61 (100 + 100)c 8/21 14 (3/21) 24 (5/21)
Pups were treated as described in “Materials and Methods.”
aTotal incidence is the number of CV tract tumors per total number of mice treated. bSome mice had more than one type
of CV tract tumor. cEqual concentrations of OH-PCB-30 and OH-PCB-61 were used as a mixture. *p < 0.05 versus a combi-
nation of E2 (5) and OH-PCB-30 (200), Fisher exact test.Our experiments were aimed at determin-
ing a relationship between estrogenicity and
carcinogenicity for estrogenic PCBs. The ﬁrst
indication of the estrogenicity of E2 and/or
OH-PCBs in the present study was premature
vaginal opening (Table 2). OH-PCBs tested
alone or in combination facilitated premature
vaginal opening in a time frame similar to that
of E2. Both OH-PCB-30 and OH-PCB-61
have also tested positive for in vivo estrogenic-
ity in juvenile fish and mice (Carlson and
Williams 2001; Korach et al. 1988). Like other
studies testing interactions, we only found
additive effects from the combined chemicals
(Carlson and Williams 2001; Ramamoorthy
et al. 1997). We found that the highest mortal-
ity rates were seen in mice treated with high
doses of OH-PCBs, indicating that neonatal
exposure to PCBs has a chronic toxic effect
because the lethality occurred close to
12 months. Some of the chronic carcinogenic
effects attributed to OH-PCB exposure in this
study were similar to those known for E2, but
others, such as tumor formation in organs
other than the CV tract, were not. Thus, the
tumors seen in E2-treated mice reflect the
species-speciﬁc E2-mediated tumor susceptibil-
ity of BALB/cCrgl mice. In contrast to ﬁnd-
ings in the literature that mixtures of PCBs
promote hepatocellular carcinoma (Dutch
Expert Committee 1995; Mayes et al. 1998;
Sleight 1985), a variety of malignant tumors
were identiﬁed in the OH-PCB–treated mice,
but only one mouse developed a hepatocellular
carcinoma; thus, the mechanisms are likely to
be very different.
The incidence of mammary gland car-
cinomas was significantly increased to 13%
(4 of 30) in mice treated with 40 µg
OH-PCB-61. Mammary gland tumors were
also detected in mice treated with E2 (3%; 1
of 37), 400 µg OH-PCB-61 (13%; 4 of 30),
20 µg OH-PCB-30 (15%; 5 of 33), and 20 µg
OH-PCB-30/61 (8%; 3 of 36). Although sev-
eral published studies support the idea that
developmental exposure to PCBs may lead to
an increase in breast cancer (Birnbaum and
Fenton 2003; Desaulniers et al. 2001; Mayes
et al. 1998), the results from the present study
are striking in that we detected an increased
number of mammary tumors. Historically,
BALB/cCrgl mice do not develop mammary
gland tumors (Dunn and Green 1963; Mori
et al. 1976). We did not find a clear dose-
dependent increase in mammary gland tumor
responses because there were fewer mammary
gland tumors detected in the high-dose
OH-PCB-61 mice than in the low-dose
OH-PCB-61 mice. Also, we detected no
mammary gland tumors in the high dose
OH-PCB-30 mice, but 5 were found in the
low-dose OH-PCB-30 mice. This effect is
probably due to the increased mortality in
high-dose groups (Table 2). Unfortunately, no
dissections or histologic analysis occurred if
animals died on weekends or at night. In addi-
tion, the mammary glands were not dissected
out from control animals, and the only reason
mammary gland tumors were detected at all is
because they were visibly obvious.
Effects on mammary growth, lobulo-
alveolar development, and hyperplastic alveolar
nodules as well as dysplasias have been detected
(Jones and Bern 1977, 1979) in virgin female
BALB/cCrgl mice neonatally treated with
estrogen. Mammary tumors have been found
in transplantation studies (Medina 1976)
where hyperplastic alveolar nodules from 7,12-
dimethylbenz[a]anthracene-treated mice were
placed into the mammary fat pad of virgin
BALB/cCrgl mice. The average time for devel-
opment (6 of 6; 100%) of tumors was
6 months. It has been postulated that the
mouse mammary tumor virus (MMTV) is
essential for the development of mammary
gland tumors. This theory is strongly sup-
ported by ﬁndings that hormonally neonatally
treated mice that have MMTV develop mam-
mary gland tumors (Jones and Bern 1979). It
was unfortunate that the mammary gland was
not chosen as a target organ, but we did not
expect to find mammary gland tumors in
treated inbred mice that lack MMTV. The
induction of mammary gland tumors by
neonatal OH-PCB may be due to the combi-
nation of its overall carcinogenicity with its
estrogenicity. Future studies using this animal
model are necessary to determine the mecha-
nism of action. In humans, the association of
PCBs with breast cancer has not been deter-
mined. Although exposure to elevated levels of
PCBs is still a potential factor in breast cancer
(Laden et al. 2002; Wolff and Toniolo 1995),
a correlation has not been established (Brown
1987; Higginson 1985; Krieger et al. 1994;
Laden et al. 2001).
There are two significant results of this
study: the demonstration that OH-PCB con-
geners are carcinogenic, and that the type of
CV tract tumors observed in response to treat-
ment with a mixture was signiﬁcantly different
than from those found after individual
OH-PCBs treatment. For both mixture groups
(E2/OH-PCB-30, and OH-PCB-30/61), we
found a lower incidence of CV tract squamous
cell carcinomas and elevated incidence of CV
tract adenosquamous cell carcinoma. Thus, a
shift from squamous to adenosquamous was
observed in mice treated with mixtures. This is
a very interesting result because it illustrates
clearly that the toxic response to mixtures may
be different from the toxic response of the
individual components of the mixture.
Gynecologic epithelial tumors are generally
grouped into these two major categories based
on whether they are derived from Mullerian
epithelium (adenocarcinoma) or squamous
epithelium (squamous cell carcinoma) of the
urogenital sinus. The adenosquamous carci-
noma of the CV tract may be similar to the
adenosquamous carcinoma of the lung, which
is an example of a heterogeneous tumor
(Kanazawa et al. 2000). Adenosquamous car-
cinomas of the lung and CV tract are similar
in clinical outcome: the prognosis is poorer
than for patients with either squamous carci-
nomas or adenocarcinomas (Farley et al. 2003;
Hofmann et al. 1994).
The present study supports the hypothesis
that neonatal exposure to estrogenic OH-PCBs
mimics the ability of E2 to induce CV tract
tumors in the BALB/cCrgl mouse. For exam-
ple, there was an increase in CV tumors
induced by higher doses of OH-PCB-30 com-
pared with lower doses. In addition, similar
molecular and morphologic effects were true to
a lesser extent for PCB-61. The dose of
OH-PCB-61 was twice that of OH-PCB-30;
therefore, a similar incidence of CV tract
tumors was expected based on receptor binding
affinities. Instead, there was less than half as
many: incidence rates for CV tract tumors were
21% (5 of 24) versus 46% (10 of 22) for the
high doses of OH-PCB-61 and OH-PCB-30,
respectively. This may be a result of toxicity as
indicated by higher mortality (Table 2).
Assessing the long-term effects of PCBs is
important because the general population is
exposed to these chemicals at all stages of
human development. In a series of reports,
researchers from the Netherlands associated
prenatal exposure to PCBs with biologic
effects (Huisman et al. 1995; Patandin et al.
1999a, 1999b). Similarly, perinatal exposure
to PCBs is linked to a variety of immunologic,
neural, and endocrine effects and potentially
linked with biologic effects on growth, sexual
development, and long-term reproductive
health (Weisglas-Kuperus 1998). Perinatal
exposure to PCBs has been associated with
smaller head circumference and lower birth
weight (Fein et al. 1984; Taylor et al. 1989).
One study also reported a decrease in penis
size in boys born to mothers exposed to PCBs,
but this ﬁnding may be difﬁcult to interpret
because the maternal exposure was to a mix-
ture of PCBs most likely contaminated with
similar organochlorines, that is the polychlori-
nated dibenzo-p-dioxins/dibenzofurans (Guo
et al. 1995). These studies emphasize the need
for testing individual compounds and as com-
pounds in mixtures.
Conclusion
OH-PCBs induced predominantly mammary
gland and CV tract tumors in mice that were
exposed during a critical period of develop-
ment. OH-PCBs induced tumors in other
organs, suggesting that the carcinogenic effect
is not restricted to estrogen-sensitive organs.
These findings suggest that other organs
should be examined in future epidemiologic
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studies with OH-PCBs. Finally, we believe
this report is the ﬁrst to show that a chemical
mixture shifts the tumor type from squamous
to adenosquamous, suggesting that exposure
to a mixture may result in the formation of a
more aggressive tumor type.
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